Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

Background Numerous ongoing trials are testing anti-PD-1-based or anti-PD-L1-based
cancer treatment combinations. Understanding the toxicity profiles of treatment-related …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …

Immune profiling in patients with monoclonal gammopathy of undetermined significance
(MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the …

Tumor cells predominantly express self-antigens and overcoming self-tolerance is the
primary challenge to effective immunotherapy. Tumors also express ligands for co-inhibitory …

Introduction Immune-based combinations, including nivolumab plus ipilimumab,
pembrolizumab plus axitinib, and (at a lesser extent) avelumab plus axitinib, should be …

The advances in cancer immunotherapy come with several obstacles, limiting its
widespread use and benefits so far only to a small subset of patients. One of the underlying …

Background Despite recent advances in understanding the complex immunologic
dysfunction in the tumor microenvironment (TME), fewer than 20% of patients with head and …

Glycogen synthase kinase (GSK) 3β is a multifunctional serine/threonine protein kinase with
more than 100 substrates and interacting molecules. GSK3β is normally active in cells and …